Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831

Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2+ breast cancer...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JNCI Cancer Spectr
Asıl Yazarlar: Pogue-Geile, Katherine L, Song, Nan, Serie, Daniel J, Wang, Ying, Gavin, Patrick G, Kim, Rim S, Tanaka, Noriko, Fumagalli, Debora, Taniyama, Yusuke, Li, Zhuo, Rastogi, Priya, Swain, Sandra M, Mamounas, Eleftherios P, Geyer, Charles E, Wolmark, Norman, Lucas, Peter C, Paik, Soonmyung, Thompson, E Aubrey
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Brief Communication
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7674704/
https://ncbi.nlm.nih.gov/pubmed/33241186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkaa058
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller